Dr. Glaser’s Articles

  • Home
  • Dr. Glaser’s Articles

Original Publications from Dr. Glaser

Dr. Glaser has devoted her life to researching, treating, and preventing breast cancer. Prior to performing pellet insertions, Dr. Glaser was a breast cancer surgeon. She is currently researching subcutaneous testosterone therapy and breast cancer. She has evaluated and treated over 1500 breast cancer patients. At the Millennium Wellness Center, she currently treats both men and women with testosterone pellet therapy. 

Dr. Glaser believes in open access to her research. Below is a collection of her articles and presentations from various peer-reviewed journals and conferences. This information is provided as educational material only and should not be used for diagnosis or treatment. 

Additional information is hosted on trocarkit.com. Dr. Glaser’s research can also be found on ResearchGate.

Peer Reviewed Publications

Title Year Full Text Publication
Intracrinology and Testosterone Pellet Therapy: An Enzyme-Aware, Symptom-Driven Approach to Hormone Optimization in Aging 2026 Full Text Cureus
Incidence of Invasive Breast Cancer in Women Treated with Testosterone Implants: Dayton Prospective Cohort Study, 15-Year Update 2025 Full Text Adv Prev Med Health Care 8: 1070
Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors 2021 Journal of the Endocrine Society
Testosterone implant therapy in women with and without breast cancer: Rationale, Experience, Evidence 2021 Full Text Androgens: Clinical Research and Therapeutics
Testosterone/Aromatase Inhibitor Therapy in Advanced Breast Cancer: A case series 2021 Androgen Society 3rd annual meeting March 13, 2021
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102 2020 Full Text Supportive Care in Cancer
Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study 2019 Full Text BMC Cancer
Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. Supplement 1. Statistical Methods 2019 Full Text BMC Cancer
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy 2019 Full Text Int J Pharm Compd
Reduced incidence of breast cancer with testosterone implant therapy: a 10-year cohort study 2018 Full Text 2018 San Antonio Breast Cancer Symposium. 2018, December: P6-13-02
A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance A221102 2018 Full Text 2018 San Antonio Breast Cancer Symposium. 2018, December: P4-16-01
Breast cancer treatment in women over the age of 80: A tailored approach 2017 Full Text Maturitas
Testosterone, anastrozole and venous thrombosis 2017 Full Text Maturitas
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: 9-year* interim analysis 2017 Full Text Maturitas
Oral presentation and abstract. Critical role of testosterone in both sexes 2017 Full Text Maturitas
Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications Full Text Menopause
Effect of testosterone therapy on the female voice 2016 Full Text Climacteric
Testosterone and breast cancer prevention 2015 Full Text Maturitas
Reduced incidence of breast cancer in women adherent to testosterone or testosterone-anastrozole hormone therapy: updated interim analysis 2015 Full Text Maturitas
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer 2014 Full Text Menopause (New York, NY)
Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors 2014 Sep 10 Full Text J Clin Oncol
THE EFFECTS OF SUBCUTANEOUS TESTOSTERONE IMPLANTATION ON THE FEMALE VOICE 2013 Full Text 10th International Conference Advances in Quantitative Laryngology; 2013;
Testosterone therapy in women: Myths and misconceptions 2013 Full Text Maturitas
Testosterone implants in women: pharmacological dosing for a physiologic effect 2013 Full Text Maturitas
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study 2013 Full Text Maturitas
Testosterone pellet implants and migraine headaches: a pilot study 2012 Full Text Maturitas
Subgroups of patients treated with an aromatase inhibitor (anastrozole) delivered subcutaneously in combination with testosterone 2012 9th European Congress on Menopause and Andropause. Athens, GR 424; 2012;
Improvement in scalp hair growth in androgen deficient women treated with testosterone: a questionnaire study 2012 Full Text British Journal of Dermatology
58 BENEFICIAL EFFECTS OF SUBCUTANEOUS TESTOSTERONE THERAPY ON LIPID PROFILES IN WOMEN 2012 Full Text Maturitas
14 SUBGROUPS OF PATIENTS TREATED WITH AN AROMATASE INHIBITOR (ANASTROZOLE) DELIVERED SUBCUTANEOUSLY IN COMBINATION WITH TESTOSTERONE 2012 Full Text Maturitas
Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS) 2011 Full Text Maturitas
Subcutaneous testosterone-anastrozole implant therapy in breast cancer survivors 2010 Full Text
Low salivary testosterone levels in patients with breast cancer 2010 Full Text BMC cancer
The protective role of androgens: salivary hormone levels in newly diagnosed breast cancer patients 2009 26th Annual Miami Breast Cancer Conference: March 4-7, 2009; Miami, FL;
Safety of maternal testosterone therapy during breast feeding 2009 Full Text International journal of pharmaceutical compounding
Efficacy of testosterone therapy delivered by pellet implant 2009 Full Text Maturitas
Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina 2008 Full Text Gynecologic and obstetric investigation
The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy 2002 Full Text Annals of surgical oncology
Accuracy of sentinel lymph node biopsy for patients with T-2 and T-3 Breast cancer (vol 67, pg 522, 2001) 2002 Full Text AMERICAN SURGEON
Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multi-institutional study 2001 Full Text Annals of surgery
Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques 2001 Full Text Annals of surgery
Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used 2000 Full Text Journal of Clinical Oncology
Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes 2000 Full Text Annals of surgery
Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study 2000 Full Text Surgery
ORIGINAL REPORTS-Breast Cancer-Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique Is Used 2000 Journal of Clinical Oncology
Sentinel lymph node biopsy for breast cancer: A suitable alternative to routine axillary dissection in multiinstitutional practice when optimal technique is used 2000 Full Text J Clin Onco
Correlation of FDG PET and sentinel lymph node biopsy in patients with breast cancer 2000 Full Text JOURNAL OF NUCLEAR MEDICINE
FDG PET IN BREAST-CANCER 1994 Journal of Nuclear Medicine
Arteriovenous fistulas after cardiac catheterization 1989 Full Text Archives of Surgery
Chronic esophageal ulcers in an AIDS patient 1986 Full Text Gastrointestinal endoscopy

Why Testosterone Pellet Therapy?

Subcutaneous testosterone pellet therapy offers a superior alternative to traditional hormone replacement therapies (HRT), injections, and gels.

What You’ll Get in a Consultation:

By incorporating testosterone pellet therapy into your practice, you can provide your patients with a research-backed, life-changing treatment option.

How to Get Started

We make it easy for healthcare professionals to integrate testosterone therapy into their practice.

Testimonials from Healthcare Providers

FAQ's

Why pellets?

Pellets deliver consistent, healthy levels of hormones for 3-4 months in women and 4-5 months in men. They avoid the fluctuations, or ups and downs, of hormone levels seen with every other method of delivery. This is important for optimal health and disease prevention. Pellets do not increase the risk of blood clots like conventional or synthetic hormone replacement therapy.

In studies, when compared to conventional hormone replacement therapy, pellets have been shown to be superior for relief of menopausal symptoms, maintenance of bone density, restoration of sleep patterns, and improvement in sex drive, libido, sexual response and performance.
Testosterone delivered by a pellet implant, has been used to treat migraine and menstrual headaches. It also helps with vaginal dryness, incontinence, urinary urgency and frequency. In both men and women, testosterone has been shown to increase energy, relieve depression, increase sense of well being, relieve anxiety and improve memory and concentration. Testosterone, delivered by pellet implant, increases lean body mass (muscle strength, bone density) and decreases fat mass. Men and women need adequate levels of testosterone for optimal mental and physical health and for the prevention of chronic illnesses like Alzheimer's and Parkinson's disease, which are associated with low testosterone levels.

Even patients who have failed other types of hormone therapy have a very high success rate with pellets. There is no other ‘method of hormone delivery' that is as convenient for the patient as the implants. Implants have been used in both men and women since the late 1930's. There is significant data that supports the use of testosterone implants in both men and women.


What are signs and symptoms of androgen (testosterone) deficiency in men and women?

Bone loss, joint discomfort, pain, inflammation
Sarcopenia, muscle loss, aches, decreased strength
Changes in cognition, mental focus, and memory
Insomnia, sleep disturbance
Urinary incontinence, vaginal dryness, prostate issues
Diminished sense of well-being
Dysphoric mood (sadness, depression, anxiety, irritability)
Persistent, unexplained fatigue
Sexual – decreased performance, libido, receptivity and pleasure
Vasomotor instability (hot flashes), heart discomfort (A-Fib)

How and where are pellets inserted?

The insertion of pellets is a simple, relatively painless procedure done under local anesthesia. The pellets are usually inserted in the lower abdominal wall or upper buttocks through a small incision, which is then closed with a skin tape (steri-strip). The experience of the health care professional matters a great deal, not only in placing the pellets, but also in determining the correct dosage of hormones to be used.

Are there any side effects or complications from the insertion of the pellets?

Complications from the insertion of pellets include minor bleeding or bruising, discoloration of the skin, infection, and the possible extrusion of the pellet. Other than slight bruising, or discoloration of the skin, these complications are rare.
Testosterone may cause a slight increase in facial hair in some women. Testosterone stimulates the bone marrow and increases the production of red blood cells. A low testosterone level in older men is a cause of anemia. Testosterone, delivered by implants or other methods, can cause an elevation in the red blood cells. If the hemoglobin and hematocrit (blood count) get too high, a unit of blood may be donated.
After the insertion of the implants, vigorous physical activity is avoided for 48 hours in women and up to 5 to 7 days in men. Early physical activity is a cause of ‘extrusion', which is a pellet working it's way out. Antibiotics may be prescribed if a patient is diabetic or has had a joint replaced. However, this is a ‘clean procedure' and antibiotics may not be needed.

Why haven't I heard about Pellets?

You may wonder why you haven't heard of pellets. Pellets are not patented and have not been marketed in the United States. They are frequently used in Europe and Australia where pharmaceutical companies produce pellets. Most of the research on pellets is out of Europe and Australia. Pellets were frequently used in the United States from about 1940 through the late 70's when oral patented estrogens were marketed to the public. In fact, some of the most exciting data on hormone implants in breast cancer patients is out of the United States. Even in United States, there are clinics that specialize in the use of pellet implants for hormone therapy.

Do men need hormone therapy?

Testosterone levels begin to decline in men beginning in their early 30's. Most men maintain adequate levels of testosterone into their mid 40's to mid 50's, some into their late 70's to early 80's. Men should be tested when they begin to show signs of testosterone deficiency. Even men in their 30's can be testosterone deficient and show signs of bone loss, fatigue, depression, erectile dysfunction, difficulty sleeping and mental decline. Most men need to be tested around 50 years of age. It is never too late to benefit from hormone therapy. In addition, as men age and their testosterone level declines, estrogen levels may increase. Elevated estrogen may prevent optimal results from testosterone therapy and cause problems like weight gain, fluid retention and anxiety, as well as have an adverse effect on the prostate gland. It is important to have both testosterone and estradiol levels measured.

What if my primary care physician or my gynecologist says that there is ‘no data' to support the use of testosterone implants?

He or she is wrong. There is a big difference between ‘no data' and not having read the data. It is much easier for busy practitioners to dismiss the patient, than it is to question their beliefs and do the research. It's about a patient making an informed choice. After testosterone pellets are inserted, patients may notice that they have more energy, sleep better and feel happier. Muscle mass and bone density will increase while fatty tissue decreases. Patients may notice increased strength, co-ordination and physical performance. They may see an improvement in skin tone and hair texture. Concentration and memory may improve as will overall physical and sexual health. There is also data to support the ‘long term' safety of testosterone delivered by pellet implants.

Do testosterone implants have the same danger of breast cancer as other forms of hormone replacement therapy?

Testosterone, delivered by pellet implantation, has been shown to decrease breast proliferation and lower the risk of breast cancer, even in patients on conventional hormone replacement therapy. Clinical studies show that testosterone balances estrogen and is breast protective. In the past, testosterone implants have been used to treat patients with advanced breast cancer. In 1940, it was theorized that treating patients with testosterone implants earlier, at the time of diagnosis, would have an even greater benefit, preventing recurrent disease. Androgens have also been shown to enhance the effect of Tamoxifen® therapy in breast cancer patients. References supporting these statements can be found in the data section of the website in the ‘Breast Cancer Folder'.

In contrast to testosterone, Estradiol, whether delivered by pellet implant*, applied topically to the skin or taken orally has been shown to increase the risk of breast cancer. This is not surprising, as continuous Estradiol, a strong estrogen, has been shown to stimulate breast tissue.

*Million Women’s Study

Can breast cancer patients be treated with testosterone pellets? Is it safe?

Testosterone prevents the growth of hormone receptor positive breast cancer and has been used to treat breast cancer for over 80 years. However, testosterone can be aromatized to estradiol, which can stimulate a breast cancer. The testosterone must be combined with an aromatase inhibitor like anastrozole or letrozole, which prevents the conversion of testosterone to estrogen. The combination implants safely relieve symptoms in breast cancer survivors, decrease recurrence and increase survival. Breast cancer tumors also respond to therapy.

Are there other hormones besides testosterone that have not been shown to increase the risk of breast cancer?

Bio-identical progesterone (including FDA approved Prometrium®) has not been shown to increase the risk of breast cancer like the synthetic progestins. In addition, progesterone, used vaginally, does not negate the beneficial effects of estrogen on the heart like the synthetic progestins.

Estriol is a bio-identical estrogen widely used in Europe that does not bind strongly to estrogen receptor and does not stimulate breast tissue. We have shown that pre-menopausal women diagnosed with breast cancer had lower levels of estriol than controls, i.e. women without breast cancer. Numerous studies have shown that vaginal estriol does not increase the risk of breast cancer (RR 0.7). It has safely been used in breast cancer survivors. ‘High dose’ (>25 mcg) vaginal estrogens like Estrace® (estradiol) and vaginal Premarin® provide systemic levels of strong estrogens that may stimulate breast tissue. However, Vagifem®, which delivers smaller doses of estrogen (10 mcg) is considered ‘local’ therapy and may be a safe option for vaginal hormone therapy in breast cancer patients. If you are a breast cancer survivor, it is important that your physician understands this concept.

Why isn’t estrogen therapy or Estradiol pellet therapy recommended?

We have shown that symptoms, including hot flashes, are relieved with continuous testosterone alone. Testosterone delivered by pellet implant is extremely effective therapy. In addition, it does not have the unwanted side effects of estrogen therapy. Over half of women treated with estrogen (especially the pellet implant) will experience uterine bleeding. If a menopausal patient has bleeding, she must notify her physician and have an evaluation, which may include a vaginal ultrasound and endometrial biopsy. Estrogen also stimulates the breast tissue can cause breast pain and cysts. It also increases the risk of breast cancer. Higher levels of estrogen (in the second half of the menstrual cycle) are needed for pregnancy. Most women feel better with lower levels of estrogen.

Almost all symptoms, including hot flashes, are relieved with testosterone pellets alone. A study by Sherwin in 1985 looked at testosterone, testosterone with estradiol, estradiol alone and placebo. The group of women who responded best (somatic, psychological and total score)…testosterone alone! The groups that did the worst…estrogen alone and placebo. Higher levels of testosterone were associated with a better response. These results are expected. Testosterone is the major ‘substrate’ for estrogen production in the brain, bones, vascular system, breast and adipose tissue. Some physicians do not understand this and may insist that estrogen therapy is needed.

Excess estrogen can cause anxiety, weight gain, belly fat, tender breasts, emotional lability, symptoms of PMS, and mood swings. Long-term exposure to stronger estrogens like estradiol and Premarin can increase the risk of breast cancer. In addition, there is exposure to many estrogen-like chemicals.

Some women (and men) ‘aromatize’ or convert too much testosterone to estradiol, which can interfere with the beneficial effects of testosterone. An ‘aromatase inhibitor’ (i.e. anastrozole) may be prescribed to prevent this. Patients, including breast cancer survivors and men with elevated estrogens, may be treated with the combination testosterone-anastrozole implants.

Will hormone therapy with testosterone pellets help with hair loss?

Hormone deficiency is a common cause of hair loss and treatment with testosterone implants can help to regrow hair. Hair becomes thicker and less dry with pellet therapy. Click here for more information ‘Hair Health and Hormone Balance'

Do testosterone pellets cause voice changes in women?

Although there are abundant claims of ‘voice deepening’ with testosterone therapy we have not seen this in clinical practice. Therapeutic levels of testosterone, delivered by subcutaneous implant, had no adverse effect on the female voice including lowering or deepening of the voice.

Do testosterone pellets increase the risk of blood clots?

No, subcutaneous testosterone pellets do not increase the risk of blood clots. Non-oral testosterone ‘bypasses the liver’ and does not increase clotting factors. However, estrogen levels should be monitored: increased estrogen can affect blood clotting.

How long until a patient feels better after pellets are inserted?

Some patients begin to ‘feel better' within 24-48 hours while others may take a week or two to notice a difference. Diet and lifestyle, along with hormone balance are critical for optimal health. Stress is a major contributor to hormone imbalance and illness. Side effects and adverse drug events from prescription medications can interfere with the beneficial effects of the testosterone implant.

How long do pellets last?

The pellets usually last between 3-4 months in women and 4-5 months in men. The pellets do not need to be removed. They completely dissolve on their own.

Do patients need progesterone when they use the pellets?

No. Women who are treated with testosterone implants alone (no estrogen therapy) do not require progestin therapy.

However, if estradiol, or other estrogen therapy is prescribed, progestins are also needed. The main indication for the use of synthetic progestins, like Provera® or progesterone, is to prevent the proliferation (stimulation) of the uterine lining caused by estrogen. Progestin therapy is NOT required if estrogen therapy is not prescribed. However, there may be other health benefits from the hormone, progesterone. It may help with anxiety or insomnia. Interestingly, progesterone implants have been used since the 1940’s.

How are hormones monitored during therapy?

Hormone levels may be drawn and evaluated before therapy is started. This may include an FSH, estradiol, and testosterone (free and total) for women. Men need a PSA (prostate specific antigen), sensitive estradiol, testosterone, LH, liver profile and blood count prior to starting therapy. Thyroid hormone levels (TSH) may also be evaluated.

In men, follow up levels, including a PSA, blood count and estradiol, may be obtained prior to subsequent testosterone implantation. Men must notify their primary care physician and obtain a digital rectal exam each year. Women are advised to continue their monthly self-breast exam and obtain a mammogram and/or pap smear as advised by their gynecologist or primary care physician.

How much does this cost?

The cost for the insertion of pellets is between $260 and $560 depending on the dose of the hormone and the number of pellets needed. Men need a much larger dose of testosterone than women and the cost is higher. Pellets need to be inserted 2 to 4 times a year depending on how rapidly a patient metabolizes hormones. There is also an initial consultation fee.
When compared to the cost of drugs to treat the individual symptoms of hormone decline, pellets are very cost effective.

Will insurance cover the procedure?

Some insurance companies cover the cost of pellets, especially in men. Others do not. Most physicians require payment for their services. Patients may want to contact their insurance companies to see if their costs will be reimbursed. Prevention is much more cost effective than disease.
Patients are able to ‘appeal' a denied claim.

Is there a role for testosterone implants (pellets) in a pre-menopausal female?

Testosterone pellets may be used in pre-menopausal females (women who have not stopped menstruating). Testosterone has been shown to relieve migraine or menstrual headaches, help with symptoms of PMS (premenstrual syndrome), relieve anxiety and depression, increase energy, help with sleep and improve sex drive and libido. If a pre-menopausal female has a testosterone pellet inserted, she must use birth control. There is a theoretical risk of ‘masculinizing’ a female fetus (giving male traits to a female fetus).

Can a patient be allergic to the implants?

Very rarely, a patient will develop local zone of redness (3-8 cm) and itching at the site of the testosterone implant. There is minimal or no tenderness and no other sign of infection. Pellets are made of up testosterone, stearic acid and PVP (povidone). Patients may react to the PVP. Implants can be compounded or made without PVP. Many patients who develop a local reaction to the implant have low cortisol levels and upon further questioning, have symptoms of adrenal insufficiency. Cortisol testing may be recommended. If needed, 25-50 mg of Benadryl works well for the itching. See handout ‘Local allergic reaction’ for further recommendations.

Join the Future of Hormone Therapy

Ready to enhance your expertise and patient outcomes? Partner with us to integrate testosterone pellet therapy and bring research-based hormone therapy to more patients.

228 E Spring Valley Pike, Dayton, OH 45458

Mon – Fri: 9AM – 5PM EST, Sat – Sun: Closed, Holidays: Special hours may apply

Cart

No products in the cart.

Search
Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare